Abstract
To evaluate the possible association between benzodiazepine use and subsequent cancer risk in Taiwan. In this population-based retrospective cohort study, we used data from 1996 to 2000 from the Taiwanese National Health Insurance system to investigate the possible association between benzodiazepine use and cancer risk. The exposure cohort (mean age = 47.9 years, standard deviation [SD] = 17.3 years) consisted of 59,647 patients with benzodiazepine use. Each patient from the exposure cohort was randomly frequency-matched by age and sex to a person from the cohort with no benzodiazepine exposure (the comparison group; mean age = 46.4 years, SD = 17.8 years). Each study subject was followed until a diagnosis of cancer was made (according to ICD-9-CM) or until the time the subject was censored for loss to follow-up, death, or termination of insurance-or to the end of 2009. A Cox proportional hazard regression analysis was conducted to estimate the effects of benzodiazepine use on cancer risk. In the group with benzodiazepine use, the overall risk of developing cancer was 19% higher than in the group without benzodiazepine exposure, and the difference between the groups was statistically significant (hazard ratio [HR] = 1.19; 99.6%...Continue Reading
Citations
Mar 6, 2013·PloS One·Cheng-Che ShenChia-Jen Liu
Oct 5, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Shiyao HeYe Zhang
Mar 22, 2014·BMJ : British Medical Journal·Scott WeichMartin Frisher
Nov 14, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Daniel F Kripke
Sep 27, 2016·International Journal of Cancer. Journal International Du Cancer·Hong-Bae KimByoungjin Park
Nov 18, 2016·BMC Urology·Yung-Chan ChenShiu-Dong Chung
Jun 10, 2017·British Journal of Clinical Pharmacology·Lau Caspar ThygesenJesper Hallas
Nov 29, 2016·Current Medical Research and Opinion·Tomor HarnodChun-Hung Tseng
Sep 3, 2017·Drugs in R&D·Jaden Brandt, Christine Leong
Nov 26, 2015·F1000Research·Daniel F Kripke
Jun 16, 2016·F1000Research·Daniel F Kripke
Feb 15, 2019·BMC Cancer·Wei-Sheng Chung, Cheng-Li Lin
Feb 13, 2015·Medicine·Usman IqbalYu-Chuan Jack Li
Dec 20, 2017·Oncotarget·Tao ZhangYi Zhou
Sep 17, 2015·Medicine·Tomor HarnodChia-Hung Kao
Jan 23, 2016·Pharmacoepidemiology and Drug Safety·Chao-Feng LinLi-Nien Chien
Sep 6, 2020·European Journal of Nutrition·Marie BeslayMathilde Touvier
May 19, 2016·F1000Research·Daniel F Kripke
May 16, 2014·Psychiatry and Clinical Neurosciences·Wei-Shih HuangChia-Hung Kao
Aug 2, 2014·British Journal of Clinical Pharmacology·Daniel F Kripke, Robert D Langer
Aug 2, 2014·British Journal of Clinical Pharmacology·Anton PottegårdJesper Hallas
Mar 24, 2020·Expert Opinion on Pharmacotherapy·Amanda B HassingerAli A El-Solh
Oct 7, 2020·Medicina·Tzu-Rong PengYou-Chen Chao
Sep 30, 2021·Molecular and Clinical Oncology·Raffaele BaioManlio Schettini